Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)

Summary

The purpose of this study is to assess the potential use of delta-inulin as an adjuvant to facilitate the desired immune response to Jack Jumper Ant (JJA) venom with a lower dose of venom, thus reducing adverse reactions, venom requirements and costs of treatment. Specifically we aim to compare outcomes of in-hospital JJA sting challenges and JJA venom specific IgE, and IgG4 responses to semi-rush JJA VIT at maintenance doses of 25 and 50 mcg of JJA venom, with and without delta-inulin adjuvant.

Timeline

Start

2016-10

Primary completion

2021-12

Completion

2021-12

Outcome

Missed primary endpoint

paper There was no difference between groups for sting challenge outcome (p = 0.98) PMID 41748259 ↗

paper Challenge outcomes were similar for all groups, with no significant difference found between 25 and 50 mcg maintenance dose or between treatment with and without Advax. PMID 41748259 ↗

Publications

• Le TA, Wanandy T, Perkins GB, Lester S, Lau WY, Turner M, Woodman RJ, Mulcahy EM, Joseph SV, Mhatre S, Brown SGA, Wiese MD, Petrovsky N, Heddle RJ, Hissaria P. A Pilot Randomised Controlled Dose-Ranging Trial of Ant Venom Immunotherapy With and Without Delta-Inulin Adjuvant. Clin Exp Allergy. 2026 Apr;56(4):378-390. doi: 10.1111/cea.70261. Epub 2026 Feb 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Delta Inulin	Other / unclassified	5 mg	—

Indications